The US Department of Health and Human Services (HHS) has agreed to buy 500,000 remdesivir treatment courses, in the wake of clinical trials revealing the drug can help patients recover from the faster. A five-day course will cost $2,340,or $3,120 for commercially insured patients, biotech firm Gilead Sciences said.
Early last month, the Food and Drug Administration issued an emergency authorization for remdesivir to be used in cases of COVID-19 where patients were “hospitalized with severe disease,” shortly after the drug showed “clear-cut positive effect” in a US trial.
“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it,” HHS Secretary Alex Azar said in a release.
This story will be updated shortly.
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.